Neurocrine Biosciences Inc vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while iShares 1 3 Year Treasury Bond ETF trades at $81.9. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| NBIX | SHY | |
|---|---|---|
Market Cap | $17.40B | — |
Sector | Health | Fixed Income |
52-Week High | $180.55 | $83.18 |
52-Week Low | $123.10 | $81.79 |
Enterprise Value | $16.49B | — |
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →